The ECTRIMS Podcast

The European Committee for Treatment and Research in Multiple Sclerosis

The ECTRIMS Podcast is a sounding board for MS experts & advocates to discuss innovative work in MS research, treatment and care with the greater MS research community, while offering a collaborative platform for MS and healthcare experts to promote & nurture the advancement of research.

  1. vor 5 Tagen

    MS Research Briefs: MRI Biomarkers, Machine Learning and the Future of MS Diagnosis

    Welcome to MS Research Briefs, a new ECTRIMS podcast series delivering an expert guided tour of important new studies in multiple sclerosis research. In each episode, leading MS experts will take a small number of recently published studies and go beyond the headline findings – exploring what the research shows and how it may influence clinical practice and future discovery. In this inaugural episode, Prof. Alan Thompson and Prof. Olga Ciccarelli discuss two studies exploring how advanced MRI biomarkers and machine learning may transform the diagnosis and prognosis of multiple sclerosis. Featured Publications Paramagnetic Rim Lesions and Development of Clinical MS in Radiologically Isolated Syndrome. JAMA Neurology. 2026;83(3):250–258. Machine learning-based combination of the central vein sign, cortical lesions and paramagnetic rim lesions: a web-based tool for the diagnosis of multiple sclerosis. Brain Communications. 2026;8(2):fcag079. Discussed in this episode Can paramagnetic rim lesions identify individuals with radiologically isolated syndrome (RIS) who are most likely to develop clinical MS? Why do paramagnetic rim lesions appear to be stronger prognostic biomarkers while the central vein sign remains a powerful diagnostic biomarker? Can machine learning models combining MRI biomarkers outperform traditional dissemination-in-space criteria? What role might advanced MRI biomarkers play in future diagnostic criteria and treatment decisions? How close are we to AI-supported diagnosis and automated biomarker detection in routine clinical practice? As advanced MRI biomarkers move from research tools towards clinically meaningful decision-making, this episode explores one of the most important developments in contemporary MS research.

    24 Min.

  2. 18. Juni

    Vitamin D and Multiple Sclerosis: Separating Evidence from Expectation

    Vitamin D and multiple sclerosis have been linked for decades, but how strong is the evidence – and what does it mean for clinical practice? In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Eric Thouvenot from University Hospital of Nimes and Dr. Deborah Mason from Christchurch Hospital about the evolving science behind vitamin D and MS. Together, they explore: Why vitamin D deficiency is associated with increased MS risk The influence of latitude, sunlight exposure and genetics How vitamin D affects immune regulation and inflammation Findings from recent vitamin D supplementation trials As researchers continue to investigate vitamin D's role in MS, this episode provides a balanced look at what we know, what remains uncertain, and what it means for patient care.

    31 Min.

  3. 3. Juni

    Can the revised 2024 McDonald Diagnostic criteria solve the misdiagnosis problem in multiple sclerosis?

    In this episode of the ECTRIMS Podcast, recorded in collaboration with the Multiple Sclerosis Journal "Controversies in MS" series, host Prof. Anneke van der Walt moderates a discussion between Prof. Andy Solomon and Prof. Enrique Gómez on one of the most debated developments in modern multiple sclerosis diagnosis. Together, they explore: • Why misdiagnosis remains a major challenge in MS care • The role of the central vein sign (CVS) and paramagnetic rim lesions (PRLs) in improving specificity • Whether expanding diagnostic sensitivity may increase false positives • The practical realities of implementing advanced MRI biomarkers globally • The importance of radiology training, implementation science, and AI-assisted imaging • How clinicians should approach MRI interpretation in real-world practice This conversation examines the balance between earlier diagnosis, diagnostic accuracy, and equitable implementation of emerging diagnostic tools across different healthcare settings. This episode is part of the MS Journal Controversies in MS series on The revised 2024 McDonald criteria can solve the misdiagnosis problem in MS. The accompanying Yes, No, and Commentary articles are available to read open access for the next month, compliments of MS Journal.

    33 Min.
  4. EBV and Multiple Sclerosis: Could Infection Hold the Key to MS?

    15. Mai

    EBV and Multiple Sclerosis: Could Infection Hold the Key to MS?

    Epstein–Barr virus (EBV) has become one of the most intensely studied topics in multiple sclerosis research. But how strong is the evidence linking EBV to MS, and could targeting the virus change the future of treatment and prevention? In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Gavin Giovannoni and Prof. Tomas Olsson about the evolving science connecting infections, immunity and multiple sclerosis. Together, they explore: Molecular mimicry and how EBV proteins may trigger autoimmune responses Whether EBV contributes to chronic CNS inflammation and disease progression Emerging therapeutic approaches including antivirals, CAR-T cells, and vaccines This conversation examines one of the most important scientific questions in MS research  and the therapeutic possibilities that may emerge from it.

    29 Min.
  5. Fenebrutinib in Relapsing MS: FENhance Trial Results Explained

    22. Apr.

    Fenebrutinib in Relapsing MS: FENhance Trial Results Explained

    New Phase 3 data presented at the AAN conference 2026 provide compelling evidence that fenebrutinib may represent a high-efficacy oral treatment option for people living with relapsing multiple sclerosis. In this exclusive episode, leading experts Prof. Ludwig Kappos from University of Basel and Dr. Jiwon Oh from Barlo MS Centre join host Brett Drummond to unpack the full FENhance 1 & 2 trial results. Together, they explore: How fenebrutinib performed against teriflunomide in relapsing MS Why BTK inhibition continues to generate strong interest across the MS treatment landscape What the results reveal about relapse reduction, MRI outcomes, and disability progression What the safety profile of fenebrutinib looked like in this cohort of patients Listen for a deep dive into the science, clinical context, and future implications for MS care.

    26 Min.
  6. How MRI and OCT are Changing Multiple Sclerosis Diagnosis, Prognosis, and Treatment

    8. Apr.

    How MRI and OCT are Changing Multiple Sclerosis Diagnosis, Prognosis, and Treatment

    Imaging techniques in multiple sclerosis are evolving rapidly, with MRI and emerging biomarkers playing a central role in diagnosis, prognosis and disease monitoring. In this episode of the ECTRIMS Podcast, neurologist Gabriel Bsteh and host Brett Drummond explore how MRI, optical coherence tomography (OCT), and imaging biomarkers are reshaping the way clinicians diagnose and manage MS. They discuss the 2024 updates to the McDonald diagnostic criteria, including the introduction of the central vein sign (CVS), paramagnetic rim lesions (PRL), and the inclusion of the optic nerve. The episode also examines how imaging biomarkers may be used to: Predict disease progression Provide prognostic information at diagnosis Monitor neuro-axonal damage over time Support treatment decisions and personalised medicine This episode is essential listening for anyone interested in multiple sclerosis, MRI, OCT, biomarkers, and advances in MS research and care.

    25 Min.
  7. Does the Label Given to My MS Disease Course Matter?

    19. März

    Does the Label Given to My MS Disease Course Matter?

    How much do the labels used to describe multiple sclerosis actually reflect the lived experience of people affected by the disease? In this first episode of the new ECTRIMS–MS Journal collaboration series, host Dr. Anneke van der Walt, Controversies Editor at the Multiple Sclerosis Journal, speaks with Jon Strum, MS caregiver and host of the RealTalk MS podcast, and Kathryn Smith, patient advocate and volunteer with the National MS Society, and person living with MS. Together they explore a deceptively simple question: does the label given to an MS disease course actually matter? Jon argues that disease labels shape perception, communication and expectations for people living with MS and their families. Kathryn explains why those same labels increasingly fail to capture the day-to-day reality of living with the disease. They discuss: Why traditional MS disease course labels can feel disconnected from lived experience The emotional and practical impact of terms such as relapsing-remitting and secondary progressive The concept of PIRA (progression independent of relapse activity) and what it reveals about MS progression Why functional outcomes and patient experience should play a greater role in how MS is described The importance of patient voice in research, clinical conversations and scientific publishing   Although they begin from opposing viewpoints, Jon and Kathryn ultimately arrive at a shared conclusion: the MS community may need a new language — one that better reflects biology, individual experience and the realities of living with the disease. Note: This episode is part of the MS Journal Controversies in MS series, specifically its new Controversies: Patient Voice section – a dedicated space highlighting the lived experiences of people affected by MS. Please see the following articles for more information: "Yes" – The label does matter "No" – The label does not matter Commentary

    24 Min.
  8. Rehabilitation in MS and the Case for Early Intervention

    25. Feb.

    Rehabilitation in MS and the Case for Early Intervention

    Rehabilitation is more than exercise – it is a personalised process of learning and adaptation that empowers people living with MS to maximise independence, participation and quality of life. In this episode –  recorded at ECTRIMS 2025 in Barcelona during the joint ECTRIMS–RIMS meeting – host Brett Drummond speaks with Prof. Roshan das Nair from SINTEF and Dr. Blanca de Dios Pérez from University of Nottingham about the evolving role of rehabilitation in MS care. They explore: ·      Why rehabilitation should be integrated from diagnosis ·      The rise of vocational rehabilitation and supporting people to remain in work ·      Mental health as a core component of MS care ·      Digital technologies for cognitive screening and personalised triage ·      The importance of implementation — turning research into real-world care ·      Moving toward a "community of care" model beyond the clinic As MS care advances, rehabilitation remains essential for translating medical progress into meaningful everyday outcomes.

    22 Min.
Alle anzeigen (78)

Info

The ECTRIMS Podcast is a sounding board for MS experts & advocates to discuss innovative work in MS research, treatment and care with the greater MS research community, while offering a collaborative platform for MS and healthcare experts to promote & nurture the advancement of research.

Informationen

  • Erstellt von
    The European Committee for Treatment and Research in Multiple Sclerosis
  • Jahre aktiv
    2022 - 2026
  • Folgen
    78
  • Bewertung
    Unbedenklich
  • Copyright
    © 2022
  • Sendungswebsite
    The ECTRIMS Podcast

Das gefällt dir vielleicht auch